Propanc Biopharma reports preclinical PDAC data, plans Phase 1b in Q1 2027

Propanc Biopharma said it reported preclinical PRP data in advanced pancreatic cancer models and plans a multicenter, open-label Phase 1b first-in-human study in Q1 2027, with PRP holding FDA Orphan Drug Designation for pancreatic cancer.